<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04330729</url>
  </required_header>
  <id_info>
    <org_study_id>REG-018-2018</org_study_id>
    <nct_id>NCT04330729</nct_id>
  </id_info>
  <brief_title>The Effect of Salicylate on Platelet Function in CKD (Chronic Kidney Disease) Patients Treated With Aranesp</brief_title>
  <acronym>EPOASA</acronym>
  <official_title>The Effect of Low-dose Salicylate Treatment on Platelet Function in Patients With Renal Failure Treated With Darbepoetin Alfa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zealand University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zealand University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to&#xD;
&#xD;
        1. To determine whether treatment with Erythropoiesis-stimulating agents (in the form of&#xD;
           Aranesp®) affects platelet function, and how.&#xD;
&#xD;
        2. To determine whether salicylate treatment changes the effect of EPO (erythropoietin) on&#xD;
           platelet function.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:&#xD;
&#xD;
      It is well known that treatment with EPO increases the risk of thrombotic complications in&#xD;
      patients with chronic kidney disease, including cerebral thrombosis. The requited level of&#xD;
      Hgb for sufficient treatment has therefore been set at a relatively low level (6.8-7.3 mM).&#xD;
      One obvious potential cause of this problem is the increased thrombocytosis and platelet&#xD;
      activation caused by EPO treatment. An old investigation has shown that low-dose acetyl&#xD;
      salicylic acid (ASA) treatment can remove this effect. This investigation has not been&#xD;
      performed using modern methods to investigate platelet function, and the possible prophylaxis&#xD;
      of EPO-induced thrombosis has since received little interest.&#xD;
&#xD;
      Investigators of current study therefore propose to repeat this investigation using advanced&#xD;
      methods for assessing thrombocyte function, as a preliminary, exploratory investigation prior&#xD;
      to a later randomized controlled study.&#xD;
&#xD;
      Pre-treatment Washout (4 weeks, 6 weeks if treated with Mircera))&#xD;
&#xD;
      Patients who are not treated with ESA do not receive any treatment. Patients treated with ESA&#xD;
      stop their treatment for 4 weeks. Patients treated with Mircera ® stop treatment for 6 weeks.&#xD;
&#xD;
      Patients must not take ASA as an analgesic during the whole period of the project.&#xD;
&#xD;
      At the end of the pre-treatment period, the Standard package (blood samples) is assessed.&#xD;
&#xD;
      EPO Treatment (4 weeks) The patient is treated with darbepoetin alfa (Aranesp) in equipotent&#xD;
      doses compared to previous therapy.&#xD;
&#xD;
      After 2 weeks the Hgb is measured, and the EPO dosis adjusted if necessary at the discretion&#xD;
      of the responsible physician.&#xD;
&#xD;
      After 4 weeks, the Standard package is assessed. If the Hgb is &gt;8,0 mM or is rising rapidly&#xD;
      (&gt;1,2mM per month), the EPO dose is reduced at the discretion of the responsible physician.&#xD;
&#xD;
      EPO + ASA Treatment Aranesp treatment is supplemented with ASA (Hjertemagnyl ® 75 mg x 1&#xD;
      daily). After 4 weeks the Standard package is assessed.&#xD;
&#xD;
      If the patient develops gastrointestinal symptoms (abdominal pain, nausea or heartburn), and&#xD;
      is not already being treated with pantoprazole or other PPI (proton pump inhibitors),&#xD;
      treatment is supplemented with pantoprazole 40 mg x 1 daily.&#xD;
&#xD;
      ASA treatment withdrawal - e.g. in regard to surgery - results in discontinuation of&#xD;
      participation in the study.&#xD;
&#xD;
      Post-treatment Washout Both Aranesp and Hjertemagnyl treatment is stopped. After 4 weeks the&#xD;
      Standard package and is assessed.&#xD;
&#xD;
      Termination The indication for, and dose of ESA and ASA is prescribed at the discretion of&#xD;
      the responsible physician.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 15, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Thrombocytaggregometry</measure>
    <time_frame>16 weeks</time_frame>
    <description>Multiplate induced with arachidonic acid, ADP (adenosine diphosphate) and TRAP (Thrombin receptor-activating peptid)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>D-dimer</measure>
    <time_frame>16 weeks</time_frame>
    <description>D-dimer, (FEU mg/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MPV</measure>
    <time_frame>16 weeks</time_frame>
    <description>Mean platelet volume, (fL=femtoliters)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total platelet count</measure>
    <time_frame>16 weeks</time_frame>
    <description>Total platelet count (units per milliliters)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PDW</measure>
    <time_frame>16 weeks</time_frame>
    <description>platelet distribution width (fL = femtoliters)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IPC</measure>
    <time_frame>16 weeks</time_frame>
    <description>immature platelet count (platelets/microliter)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IPF</measure>
    <time_frame>16 weeks</time_frame>
    <description>Immature platelet fraction (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>H-IPF</measure>
    <time_frame>16 weeks</time_frame>
    <description>Highly immature platelet fraction (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ROTEM</measure>
    <time_frame>16 weeks</time_frame>
    <description>Thromboelastometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TGF-beta</measure>
    <time_frame>16 weeks</time_frame>
    <description>Transforming growth factor beta</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sP-selectin</measure>
    <time_frame>16 weeks</time_frame>
    <description>Soluble platelet selectin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombomodulin</measure>
    <time_frame>16 weeks</time_frame>
    <description>Thrombomodulin</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Erythropoietin Adverse Reaction</condition>
  <arm_group>
    <arm_group_label>Dialysis patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will tablet acetylsalicylic acid 75mg x 1 for 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetylsalicylic acid</intervention_name>
    <description>Se arm description</description>
    <arm_group_label>Dialysis patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Chronic hemodialysis, peritoneal dialysis or CKD 5 treated conservatively&#xD;
&#xD;
          -  aged 18-85&#xD;
&#xD;
          -  indication for treatment with Erythropoiesis-stimulating agents (ESA)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known allergy to ASA&#xD;
&#xD;
          2. Known contraindication to ASA, e.g. recent bleeding episode.&#xD;
&#xD;
          3. Known indication for ASA. If the patient is being treated with ASA, and the physician&#xD;
             does not find any indication for this treatment, this can be stopped, and the patient&#xD;
             included after 4 weeks.&#xD;
&#xD;
          4. Raised reticulocyte count&#xD;
&#xD;
          5. Current anticoagulant therapy, e.g. warfarin, ADP receptor inhibitor (excepting&#xD;
             short-term anticoagulant therapy in connection with dialysis)&#xD;
&#xD;
          6. Short expected length of life&#xD;
&#xD;
          7. Inability to give informed consent&#xD;
&#xD;
          8. Expected non-compliance&#xD;
&#xD;
          9. Active cancer - except for non-melanoma skin-cancer&#xD;
&#xD;
         10. Iron deficiency (defined as a reticulocyte Hgb &lt;1,8 fmol. Patients can be included&#xD;
             when their iron deficiency has been cured. .&#xD;
&#xD;
         11. Change in ESA dosis &gt;33,3% within previous 2 month&#xD;
&#xD;
         12. Fertile women. Pregnancy is excessively rare in dialysis patients. Women who are &lt;50&#xD;
             years, or who are still menstruating will be excluded from the study.&#xD;
&#xD;
         13. Stable Aranesp ® dose &lt;20 µg/week.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James G Heaf</last_name>
    <role>Study Director</role>
    <affiliation>Department of medicine, Zealand University Hospital, Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mette KOefoed, md</last_name>
    <phone>0045 93576330</phone>
    <email>mkof@regionsjaelland.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rikke Borg, md, phd</last_name>
    <email>rbor@regionsjaelland.dk</email>
  </overall_contact_backup>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 20, 2020</study_first_submitted>
  <study_first_submitted_qc>March 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2020</study_first_posted>
  <last_update_submitted>March 30, 2020</last_update_submitted>
  <last_update_submitted_qc>March 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hemodialysis</keyword>
  <keyword>platelet function</keyword>
  <keyword>erythropoietin</keyword>
  <keyword>thrombosis</keyword>
  <keyword>anaemia</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

